Investors Look to Capitalize on the Budding Green Revolution
Lithium is the uncontested fuel of the green energy revolution. One little-known small-cap lithium mining company in a renowned South American location has started attracting interest from opportunity-minded investors.
Discover this company's HUGE lithium potential

Samuel Bates Martin Insider Information



Mr. Martin joined Celldex in April 2009 as Director of Financial Reporting, Planning and Analysis and most recently served as Vice President, Finance. Prior to joining Celldex, Mr. Martin served as the Director of Finance and Corporate Compliance for Alseres Pharmaceuticals, where he was responsible for managing the financial and SEC reporting and the annual budget and planning process. Mr. Martin began his career at Ernst & Young, holding various positions prior to completing his tenure as Audit Manager, where he provided audit, review, due diligence and consulting services to public and private companies in the biotechnology, medical device, health care, high technology, manufacturing and consumer product industries. Mr. Martin received an M.B.A. from Boston University, a B.S. from Skidmore College and is a Certified Public Accountant.

How do I contact Samuel Bates Martin?

The corporate mailing address for Mr. Martin and other Celldex Therapeutics executives is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. Celldex Therapeutics can also be reached via phone at (908) 200-7500 and via email at [email protected] Learn More on Samuel Bates Martin's contact information.

Has Samuel Bates Martin been buying or selling shares of Celldex Therapeutics?

Samuel Bates Martin has not been actively trading shares of Celldex Therapeutics over the course of the past ninety days. Most recently, Samuel Bates Martin sold 9,500 shares of the business's stock in a transaction on Thursday, December 23rd. The shares were sold at an average price of $42.00, for a transaction totalling $399,000.00. Learn More on Samuel Bates Martin's trading history.

Who are Celldex Therapeutics' active insiders?

Celldex Therapeutics' insider roster includes Sarah Cavanaugh (SVP), Elizabeth Crowley (VP), Freddy Jimenez (SVP), Samuel Martin (CFO), and Diane Young (SVP). Learn More on Celldex Therapeutics' active insiders.

Are insiders buying or selling shares of Celldex Therapeutics?

In the last year, Celldex Therapeutics insiders bought shares 1 times. They purchased a total of 430 shares worth more than $19,900.40. In the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 37,661 shares worth more than $1,587,253.50. The most recent insider tranaction occured on December, 23rd when CFO Samuel Bates Martin sold 9,500 shares worth more than $399,000.00. Insiders at Celldex Therapeutics own 1.9 % of the company. Learn More about insider trades at Celldex Therapeutics.

Information on this page was last updated on 12/23/2021.

Samuel Bates Martin Insider Trading History at Celldex Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/23/2021Sell9,500$42.00$399,000.00View SEC Filing Icon  
11/15/2021Sell9,500$43.57$413,915.00View SEC Filing Icon  
8/10/2021Sell2,738$45.25$123,894.50View SEC Filing Icon  
6/9/2020Buy9,750$2.99$29,152.50View SEC Filing Icon  
See Full Table

Samuel Bates Martin Buying and Selling Activity at Celldex Therapeutics

This chart shows Samuel Bates Martin's buying and selling at Celldex Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Celldex Therapeutics Company Overview

Celldex Therapeutics logo
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Read More

Today's Range

Now: $30.78
Low: $29.33
High: $30.89

50 Day Range

MA: $32.98
Low: $27.42
High: $37.33

2 Week Range

Now: $30.78
Low: $26.26
High: $57.20

Volume

5,747 shs

Average Volume

552,996 shs

Market Capitalization

$1.44 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.69
Investor Alert: Argentina Loaded With "White Gold" Opportunity
Experts expect the global lithium market to grow by 500% due to the explosion of electric vehicles and green energy. And one small-cap company just snagged a large lithium deposit in a renowned South American location.
Read about this once-in-a-lifetime opportunity